메뉴 건너뛰기




Volumn 11, Issue , 2011, Pages

Early dissemination of bevacizumab for advanced colorectal cancer: A prospective cohort study

(16)  Zafar, S Yousuf a,b   Malin, Jennifer L c,d   Grambow, Steven C a,b   Abbott, David H b   Schrag, Deborah e   Kolimaga, Jane T a,b   Zullig, Leah L b,f   Weeks, Jane C e   Fouad, Mona N g   Ayanian, John Z h   Wallace, Robert i   Kahn, Katherine L j,k   Ganz, Patricia A l   Catalano, Paul e   West, Dee W m,n   Provenzale, Dawn a,b  


Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

EID: 80051636225     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-354     Document Type: Article
Times cited : (7)

References (34)
  • 2
    • 3242686833 scopus 로고    scopus 로고
    • The price tag on progress--chemotherapy for colorectal cancer
    • 10.1056/NEJMp048143, 15269308
    • Schrag D. The price tag on progress--chemotherapy for colorectal cancer. N Engl J Med 2004, 351(4):317-319. 10.1056/NEJMp048143, 15269308.
    • (2004) N Engl J Med , vol.351 , Issue.4 , pp. 317-319
    • Schrag, D.1
  • 3
    • 33750344252 scopus 로고    scopus 로고
    • Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events
    • Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006, 33(5 Suppl 10):S26-34.
    • (2006) Semin Oncol , vol.33 , Issue.5 SUPPL. 10
    • Hurwitz, H.1    Saini, S.2
  • 4
    • 33646872630 scopus 로고    scopus 로고
    • Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants
    • 10.1002/cncr.21907, 16639738
    • Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, Bodurka DC. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 2006, 106(11):2452-2458. 10.1002/cncr.21907, 16639738.
    • (2006) Cancer , vol.106 , Issue.11 , pp. 2452-2458
    • Elting, L.S.1    Cooksley, C.2    Bekele, B.N.3    Frumovitz, M.4    Avritscher, E.B.5    Sun, C.6    Bodurka, D.C.7
  • 5
    • 56749169353 scopus 로고    scopus 로고
    • Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
    • 10.1200/JCO.2008.16.3212, 18854571
    • Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). J Clin Oncol 2008, 26(33):5326-5334. 10.1200/JCO.2008.16.3212, 18854571.
    • (2008) J Clin Oncol , vol.26 , Issue.33 , pp. 5326-5334
    • Grothey, A.1    Sugrue, M.M.2    Purdie, D.M.3    Dong, W.4    Sargent, D.5    Hedrick, E.6    Kozloff, M.7
  • 6
    • 77956185692 scopus 로고    scopus 로고
    • Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP)
    • Cohn AL, Bekaii-Saab T, Bendell JC, Hurwitz H, Kozloff M, Roach N, Tezcan H, Feng S, Sing A, Grothey A, et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol (Meeting Abstracts) 2010, 28(15_suppl):3596.
    • (2010) J Clin Oncol (Meeting Abstracts) , vol.28 , Issue.15 SUPPL , pp. 3596
    • Cohn, A.L.1    Bekaii-Saab, T.2    Bendell, J.C.3    Hurwitz, H.4    Kozloff, M.5    Roach, N.6    Tezcan, H.7    Feng, S.8    Sing, A.9    Grothey, A.10
  • 9
    • 80052838065 scopus 로고    scopus 로고
    • Representativeness of the CanCORS participants relative to Surveillance, Epidemiology & End Results (SEER) Cancer Registries, AcademyHealth Annual Research Meeting
    • Representativeness of the CanCORS participants relative to Surveillance, Epidemiology & End Results (SEER) Cancer Registries, AcademyHealth Annual Research Meeting. , http://bcb.dfci.harvard.edu/catalano/representativenessAHabstrac15jan08.pdf
  • 10
    • 76749139644 scopus 로고    scopus 로고
    • Fast Stats: An interactive tool for access to SEER cancer statistics
    • Fast Stats: An interactive tool for access to SEER cancer statistics. , http://seer.cancer.gov/statfacts/html/colorect.html
  • 11
    • 2442696436 scopus 로고    scopus 로고
    • Prognostic importance of comorbidity in a hospital-based cancer registry
    • 10.1001/jama.291.20.2441, 15161894
    • Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004, 291(20):2441-2447. 10.1001/jama.291.20.2441, 15161894.
    • (2004) JAMA , vol.291 , Issue.20 , pp. 2441-2447
    • Piccirillo, J.F.1    Tierney, R.M.2    Costas, I.3    Grove, L.4    Spitznagel, E.L.5
  • 12
    • 33745974294 scopus 로고    scopus 로고
    • Understanding cancer patients' experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey
    • Malin J, Ko C, Ayanian J, Harrington D, Nerenz D, Kahn K, Ganther-Urmie J, Catalano P, Zaslavsky A, Wallace R, et al. Understanding cancer patients' experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey. Supp Care Cancer 2006, 14(8):837-848.
    • (2006) Supp Care Cancer , vol.14 , Issue.8 , pp. 837-848
    • Malin, J.1    Ko, C.2    Ayanian, J.3    Harrington, D.4    Nerenz, D.5    Kahn, K.6    Ganther-Urmie, J.7    Catalano, P.8    Zaslavsky, A.9    Wallace, R.10
  • 13
    • 33750302638 scopus 로고    scopus 로고
    • Bevacizumab prescribing information
    • Bevacizumab prescribing information. , http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0168lbl.pdf
  • 14
    • 0023790239 scopus 로고
    • A note on graphical presentation of estimated odds ratios from several clinical trials
    • 10.1002/sim.4780070807, 3413368
    • Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988, 7(8):889-894. 10.1002/sim.4780070807, 3413368.
    • (1988) Stat Med , vol.7 , Issue.8 , pp. 889-894
    • Galbraith, R.F.1
  • 16
    • 85101444608 scopus 로고    scopus 로고
    • Statistical Analysis with Missing Data
    • Hoboken, NJ: Wiley-Interscience, 2
    • Little RJ, Rubin DB. Statistical Analysis with Missing Data. 2002, Hoboken, NJ: Wiley-Interscience, 2.
    • (2002)
    • Little, R.J.1    Rubin, D.B.2
  • 18
    • 80052854928 scopus 로고    scopus 로고
    • Good News About Cancer. Seriously
    • Good News About Cancer. Seriously. , http://www.businessweek.com/technology/content/jun2004/tc2004063_2435_tc024.htm
  • 19
    • 1242285664 scopus 로고    scopus 로고
    • Biotechnology: identifying advances from the hype
    • 10.1038/nrd1309, 15040581
    • Glassman RH, Sun AY. Biotechnology: identifying advances from the hype. Nat Rev Drug Discov 2004, 3(2):177-183. 10.1038/nrd1309, 15040581.
    • (2004) Nat Rev Drug Discov , vol.3 , Issue.2 , pp. 177-183
    • Glassman, R.H.1    Sun, A.Y.2
  • 21
    • 0035804647 scopus 로고    scopus 로고
    • Impact of Patient and Provider Characteristics on the Treatment and Outcomes of Colorectal Cancer
    • 10.1093/jnci/93.7.501, 11287444
    • Hodgson DC, Fuchs CS, Ayanian JZ. Impact of Patient and Provider Characteristics on the Treatment and Outcomes of Colorectal Cancer. J Natl Cancer Inst 2001, 93(7):501-515. 10.1093/jnci/93.7.501, 11287444.
    • (2001) J Natl Cancer Inst , vol.93 , Issue.7 , pp. 501-515
    • Hodgson, D.C.1    Fuchs, C.S.2    Ayanian, J.Z.3
  • 23
    • 70449380364 scopus 로고    scopus 로고
    • Atherosclerosis profile and incidence of cardiovascular events: a population-based survey
    • Group tSS
    • Robinson J, Fox K, Bullano M, Grandy S, . Group tSS Atherosclerosis profile and incidence of cardiovascular events: a population-based survey. BMC Cardiovasc Dis 2009, 9(1):46. Group tSS.
    • (2009) BMC Cardiovasc Dis , vol.9 , Issue.1 , pp. 46
    • Robinson, J.1    Fox, K.2    Bullano, M.3    Grandy, S.4
  • 24
    • 75349099088 scopus 로고    scopus 로고
    • Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
    • 10.1016/j.amjcard.2009.10.014, 20152237
    • Cannon CP, Rhee KE, Califf RM, Boden WE, Hirsch AT, Alberts MJ, Cable G, Shao M, Ohman EM, Steg PG, et al. Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol 2010, 105(4):445-452. 10.1016/j.amjcard.2009.10.014, 20152237.
    • (2010) Am J Cardiol , vol.105 , Issue.4 , pp. 445-452
    • Cannon, C.P.1    Rhee, K.E.2    Califf, R.M.3    Boden, W.E.4    Hirsch, A.T.5    Alberts, M.J.6    Cable, G.7    Shao, M.8    Ohman, E.M.9    Steg, P.G.10
  • 25
    • 0035849938 scopus 로고    scopus 로고
    • Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal Cancer
    • Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal Cancer. N Engl J Med 2001, 345(2):144-146.
    • (2001) N Engl J Med , vol.345 , Issue.2 , pp. 144-146
    • Sargent, D.J.1    Niedzwiecki, D.2    O'Connell, M.J.3    Schilsky, R.L.4
  • 26
    • 0035884212 scopus 로고    scopus 로고
    • Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel
    • Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel. J Clin Oncol 2001, 19(18):3801-3807.
    • (2001) J Clin Oncol , vol.19 , Issue.18 , pp. 3801-3807
    • Rothenberg, M.L.1    Meropol, N.J.2    Poplin, E.A.3    Van Cutsem, E.4    Wadler, S.5
  • 27
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    • 10.1200/JCO.2007.14.9930, 18421054
    • Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26(12):2013-2019. 10.1200/JCO.2007.14.9930, 18421054.
    • (2008) J Clin Oncol , vol.26 , Issue.12 , pp. 2013-2019
    • Saltz, L.B.1    Clarke, S.2    Diaz-Rubio, E.3    Scheithauer, W.4    Figer, A.5    Wong, R.6    Koski, S.7    Lichinitser, M.8    Yang, T.S.9    Rivera, F.10
  • 28
    • 33750218663 scopus 로고    scopus 로고
    • Population-Based Assessment of the Surgical Management of Locally Advanced Colorectal Cancer
    • 10.1093/jnci/djj396, 17047196
    • Govindarajan A, Coburn NG, Kiss A, Rabeneck L, Smith AJ, Law CHL. Population-Based Assessment of the Surgical Management of Locally Advanced Colorectal Cancer. J Natl Cancer Inst 2006, 98(20):1474-1481. 10.1093/jnci/djj396, 17047196.
    • (2006) J Natl Cancer Inst , vol.98 , Issue.20 , pp. 1474-1481
    • Govindarajan, A.1    Coburn, N.G.2    Kiss, A.3    Rabeneck, L.4    Smith, A.J.5    Law, C.H.L.6
  • 29
    • 32944478347 scopus 로고    scopus 로고
    • Geographic and Socioeconomic Variation in the Treatment of Prostate Cancer
    • 10.1200/JCO.2005.08.755, 16204005
    • Krupski TL, Kwan L, Afifi AA, Litwin MS. Geographic and Socioeconomic Variation in the Treatment of Prostate Cancer. J Clin Oncol 2005, 23(31):7881-7888. 10.1200/JCO.2005.08.755, 16204005.
    • (2005) J Clin Oncol , vol.23 , Issue.31 , pp. 7881-7888
    • Krupski, T.L.1    Kwan, L.2    Afifi, A.A.3    Litwin, M.S.4
  • 30
    • 0026538046 scopus 로고
    • Geographic variation in the use of breast-conserving treatment for breast cancer
    • 10.1056/NEJM199204233261702, 1552911
    • Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med 1992, 326(17):1102-1107. 10.1056/NEJM199204233261702, 1552911.
    • (1992) N Engl J Med , vol.326 , Issue.17 , pp. 1102-1107
    • Nattinger, A.B.1    Gottlieb, M.S.2    Veum, J.3    Yahnke, D.4    Goodwin, J.S.5
  • 32
    • 70349434695 scopus 로고    scopus 로고
    • Breast-Conserving Surgery in Older Patients with Invasive Breast Cancer: Current Patterns of Treatment Across the United States
    • e422, 10.1016/j.jamcollsurg.2009.06.363, 19801315
    • Smith GL, Xu Y, Shih Y-CT, Giordano SH, Smith BD, Hunt KK, Strom EA, Perkins GH, Hortobagyi GN, Buchholz TA. Breast-Conserving Surgery in Older Patients with Invasive Breast Cancer: Current Patterns of Treatment Across the United States. J Am Coll Surg 2009, 209(4):425-433. e422, 10.1016/j.jamcollsurg.2009.06.363, 19801315.
    • (2009) J Am Coll Surg , vol.209 , Issue.4 , pp. 425-433
    • Smith, G.L.1    Xu, Y.2    Shih, Y.-.C.T.3    Giordano, S.H.4    Smith, B.D.5    Hunt, K.K.6    Strom, E.A.7    Perkins, G.H.8    Hortobagyi, G.N.9    Buchholz, T.A.10
  • 33
    • 78349269095 scopus 로고    scopus 로고
    • Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the medicare population
    • 10.1002/cncr.25242, 20578182
    • Fairfield KM, Lucas FL, Earle CC, Small L, Trimble EL, Warren JL. Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the medicare population. Cancer 2010, 116(20):4840-4848. 10.1002/cncr.25242, 20578182.
    • (2010) Cancer , vol.116 , Issue.20 , pp. 4840-4848
    • Fairfield, K.M.1    Lucas, F.L.2    Earle, C.C.3    Small, L.4    Trimble, E.L.5    Warren, J.L.6
  • 34
    • 77954707651 scopus 로고    scopus 로고
    • Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?
    • 10.1200/JCO.2009.26.2758, 20498408
    • Mason A, Drummond M, Ramsey S, Campbell J, Raisch D. Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?. J Clin Oncol 2010, 28(20):3234-3238. 10.1200/JCO.2009.26.2758, 20498408.
    • (2010) J Clin Oncol , vol.28 , Issue.20 , pp. 3234-3238
    • Mason, A.1    Drummond, M.2    Ramsey, S.3    Campbell, J.4    Raisch, D.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.